Business
Exercise of Warrants
Sareum Holdings PLC announced the exercise of warrants to subscribe for 20,200 new ordinary shares at 12.5 pence per share, resulting in a total consideration of £2,525 for the company. Application has been made for admission of these shares to trading on AIM, expected around October 2, 2025. Following admission, the total number of ordinary shares in issue will be 138,065,173, representing the total number of voting rights. Disclaimer*
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n\nSareum Holdings plc\n(\"Sareum\" or the \"Company\")\nExercise of Warrants\nCambridge, UK, 26 September 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to subscribe for a total of 20,200 new ordinary shares in the capital of the Company at a price of 12.5 pence per ordinary share (\"New Ordinary Shares\") for a total consideration to the Company of £2,525.\nAdmission and Total Voting Rights\nApplication has been made to the London Stock Exchange plc for the admission of the 20,200 New Ordinary Shares to trading on AIM (\"Admission\"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Thursday 2 October 2025. The New Ordinary Shares will rank pari passu with the existing ordinary shares.\nImmediately following Admission, the total number of ordinary shares in issue will be 138,065,173. and the total number of voting rights will therefore be 138,065,173, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.\nFor Further Information:\n \n\n\n\n\nSareum Holdings plc\nStephen Parker, Executive Chairman\n\n\n \n01223 497700\[email protected]\n\n\n\n\nStrand Hanson Limited (Nominated Adviser)\nJames Dance / James Bellman\n \n\n\n \n020 7409 3494\n\n\n\n\nOberon Capital (Broker)\nMike Seabrook / Nick Lovering\n \n\n\n \n020 3179 5300\n\n\n\n\nICR Healthcare (Financial PR)\nJessica Hodgson / Davide Salvi\n\n\n \n020 3709 5700\n\n\n\n\n \nAbout Sareum\nSareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.\nThe Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.\nSareum is also developing SDC-1802, a TYK2/JAK1 inhibitor...